Long-term ketogenic diet causes glucose intolerance and reduced β- and α-cell mass but no weight loss in mice

Am J Physiol Endocrinol Metab. 2014 Mar 1;306(5):E552-8. doi: 10.1152/ajpendo.00453.2013. Epub 2014 Jan 7.

Abstract

High-fat, low-carbohydrate ketogenic diets (KD) are used for weight loss and for treatment of refractory epilepsy. Recently, short-time studies in rodents have shown that, besides their beneficial effect on body weight, KD lead to glucose intolerance and insulin resistance. However, the long-term effects on pancreatic endocrine cells are unknown. In this study we investigate the effects of long-term KD on glucose tolerance and β- and α-cell mass in mice. Despite an initial weight loss, KD did not result in weight loss after 22 wk. Plasma markers associated with dyslipidemia and inflammation (cholesterol, triglycerides, leptin, monocyte chemotactic protein-1, IL-1β, and IL-6) were increased, and KD-fed mice showed signs of hepatic steatosis after 22 wk of diet. Long-term KD resulted in glucose intolerance that was associated with insufficient insulin secretion from β-cells. After 22 wk, insulin-stimulated glucose uptake was reduced. A reduction in β-cell mass was observed in KD-fed mice together with an increased number of smaller islets. Also α-cell mass was markedly decreased, resulting in a lower α- to β-cell ratio. Our data show that long-term KD causes dyslipidemia, a proinflammatory state, signs of hepatic steatosis, glucose intolerance, and a reduction in β- and α-cell mass, but no weight loss. This indicates that long-term high-fat, low-carbohydrate KD lead to features that are also associated with the metabolic syndrome and an increased risk for type 2 diabetes in humans.

Keywords: glucose intolerance; ketogenic diet; pancreatic islet; α-cell; β-cell.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biomarkers / blood
  • Chemokine CCL2 / blood
  • Diet, Carbohydrate-Restricted / adverse effects
  • Diet, Ketogenic / adverse effects*
  • Glucagon-Secreting Cells / metabolism
  • Glucagon-Secreting Cells / pathology*
  • Glucose Intolerance / etiology*
  • Glucose Intolerance / metabolism
  • Glucose Intolerance / pathology
  • Inflammation / blood
  • Insulin / blood
  • Insulin-Secreting Cells / metabolism
  • Insulin-Secreting Cells / pathology*
  • Interleukin-1beta / blood
  • Interleukin-6 / blood
  • Mice
  • Triglycerides / blood
  • Weight Loss*

Substances

  • Biomarkers
  • Chemokine CCL2
  • Insulin
  • Interleukin-1beta
  • Interleukin-6
  • Triglycerides